Cortisol metabolism and impaired glucose tolerance

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-003426-28-GB

Enrollment

Registered

2007-06-12

Start date

2007-08-10

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impared glucose tolerance MedDRA version: 9.1 Level: LLT Classification code 10018429 Term: Glucose tolerance impaired MedDRA version: 9.1 Level: LLT Classification code 10029883 Term: Obesity

Interventions

Trade Name: Carbenoxolone Product Name: Carbenoxolone Pharmaceutical Form: Capsule* INN or Proposed INN: CARBENOXOLONE SODIUM CAS Number

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI > 30kg/m2 Impared glucose tolerance age 18-65 years BP =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Metformin, sulphonylurea, insulin or TZD therapy Uncontrolled BP >150/90mmHg Serum potassium 165/100 at any point during the study Serum potassium <3.5mmol/L at any point during the study Adverse drug reaction

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether Carbenoxolone can improve blood glucose control in patients with impared glucose tolerance;Secondary Objective: To determine whether carbenoxolone increases insulin secretion, improves insuiln sensitivity and decreases lipolysis in patients with impared glucose tolerance.;Primary end point(s): The study is of a fixed duration (4 weeks active treatment and 4 weeks placebo)	—

Measure

Time frame

Main Objective: To determine whether Carbenoxolone can improve blood glucose control in patients with impared glucose tolerance;Secondary Objective: To determine whether carbenoxolone increases insulin secretion, improves insuiln sensitivity and decreases lipolysis in patients with impared glucose tolerance.;Primary end point(s): The study is of a fixed duration (4 weeks active treatment and 4 weeks placebo)

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026